Mark A. Socinski, MD

Overview

Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.

Articles

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

BMC CANCER

2024

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO OPEN

2024

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

NATURE MEDICINE

2023

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

CLINICAL CANCER RESEARCH

2023

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

The oncologist

2023

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials

JAMA ONCOLOGY

2023

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

FRONTIERS IN ONCOLOGY

2023

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

ECLINICALMEDICINE

2023

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer

CLINICAL CANCER RESEARCH

2023

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Clinical lung cancer

2023

Associated Clinical Trials

NCT05650879

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer

This study is currently enrolling.

The purpose of this study is to test the safety and early signs of efficacy of an experimental drug called ELVN-002 for the treatment of solid tumors carrying HER2 genetic alterations, in particular NSCLC and breast cancer. ...

NCT04956640

LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

This study is currently enrolling.

The main purpose of this research study (during both monotherapy and combination therapy evaluation) includes the following: To determine whether LY3537982 is safe; To identify which dose level of LY3537982, by itself or in co ...

NCT05520099

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)

This study is currently enrolling.

NCT05671510

PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

This study is currently enrolling.

The main purpose of the study is to determine whether the study drug, ONC-392, is safe and well tolerated, and whether it is effective in treating lung cancer, in comparison with a standard of care chemotherapy drug, docetaxel. ...

NCT04746924

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

This study will look at the efficacy and safety of combined treatment with 2 anticancer drugs, which are called tislelizumab (also known as BGB-A317) and BGB-A1217 compared to treatment with pembrolizumab and saline (a mix of s ...

Mark A. Socinski , MD

Overview

Articles

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Education & Training

Education

Residency

Fellowship

Specialty

Board Certifications

Associated Clinical Trials

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer

LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)

PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

Explore

Institutes